Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 12/20 | 0.73 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.38 |
| ▸ | AKT1 | P31749 | 3/20 | 0.38 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.34 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.34 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893728 | 0.95 | MDM2 (0.68) | MDM2RPS6KB1AKT1PIK3R2PGR | |
| SCHEMBL9894276 | 0.91 | MDM2 (0.61) | MDM2RPS6KB1AKT1 | |
| SCHEMBL9893830 | 0.89 | MDM2 (0.75) | MDM2PIK3R2 | |
| SCHEMBL9893655 | 0.85 | MDM2 (0.66) | MDM2 | |
| SCHEMBL1437212 | 0.84 | MDM2 (1.00) | MDM2RPS6KB1AKT1PIK3R2PGR | |
| SCHEMBL27879316 | 0.83 | MDM2 (0.63) | MDM2NR1H4 | |
| SCHEMBL1437396 | 0.82 | MDM2 (0.72) | MDM2RPS6KB1AKT1PIK3R2 | |
| Acetamide SCHEMBL27862813 | 0.82 | MDM2 (0.69) | MDM2 | |
| SCHEMBL9893741 | 0.81 | MDM2 (0.53) | MDM2KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL9893574 | 0.81 | MDM2 (0.68) | MDM2RPS6KB1AKT1PIK3R2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885RPS6KB1 2083/4885AKT1 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.